Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

BACKGROUND: Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L, Atako, Nafisah, Pugh, Cheryl, Buckner, Michelle, Chowdhury, Simon, Malik, Zafar, Russell, J Martin, Gilson, Clare, Rush, Hannah, Bowen, Jo, Lydon, Anna, Pedley, Ian, O'Sullivan, Joe M, Birtle, Alison, Gale, Joanna, Srihari, Narayanan, Thomas, Carys, Tanguay, Jacob, Wagstaff, John, Das, Prantik, Gray, Emma, Alzoueb, Mymoona, Parikh, Omi, Robinson, Angus, Syndikus, Isabel, Wylie, James, Zarkar, Anjali, Thalmann, George, de Bono, Johann S, Dearnaley, David P, Mason, Malcolm D, Gilbert, Duncan, Langley, Ruth E, Millman, Robin, Matheson, David, Sydes, Matthew R, Brown, Louise C, Parmar, Mahesh K B, James, Nicholas D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811484/
https://www.ncbi.nlm.nih.gov/pubmed/34953525
http://dx.doi.org/10.1016/S0140-6736(21)02437-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811484/
https://www.ncbi.nlm.nih.gov/pubmed/34953525
http://dx.doi.org/10.1016/S0140-6736(21)02437-5

Ejemplares similares